72117-60-3

Basic information

• Product Name: 2-Carboxyoxanilic acid hydrazide
• Synonyms: 2-Carboxyoxanilic acid hydrazide
• CAS NO: 72117-60-3
• Molecular Weight: 223.188
• Mol File: 72117-60-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-Carboxyoxanilic acid hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Carboxyoxanilic acid hydrazide(72117-60-3)
• EPA Substance Registry System: 2-Carboxyoxanilic acid hydrazide(72117-60-3)

Safety Data

• Hazardous Substances Data: 72117-60-3(Hazardous Substances Data)

Upstream product

• 51679-85-7 2-carboxyoxanilic acid ethyl ester 

Downstream Products

• 108098-09-5 3-[(2-Carboxy-phenylaminooxalyl)-hydrazono]-2-oxo-2,3-dihydro-1H-indole-7-carboxylic acid 
• 108098-01-7 2-{[5-Nitro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene-hydrazinooxalyl]-amino}-benzoic acid 
• 108097-98-9 2-Carboxyoxanilic 2-oxoindolinyliden-3-hydrazide 
• 108097-99-0 2-{[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidene-hydrazinooxalyl]-amino}-benzoic acid 
• 243989-96-0 2-((5-Mercapto-[1,3,4]oxadiazole-2-carbonyl)-amino)-benzoic acid 
• 108098-00-6 2-{[5-Bromo-1-methyl-2-oxo-1,2-dihydro-indol-(3Z)-ylidene-hydrazinooxalyl]-amino}-benzoic acid 

Relevant articles and documents

Modulators of protein tyrosine phosphatases (PTPases)

The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, wherein A, R1, R2, R3, R4, R16and R17are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.